The top five types of adverse events (AE) caused by isocitrate dehydrogenase inhibitors are: general disorders and administrative site conditions (1,637 cases, 40.2%), injury poisoning and procedural complications (924 cases, 22.7%), investigations (803 cases, 19.7%), gastrointestinal disorders (685 cases, 16.8%), neoplasms benign malignant and unspecified incl cysts and polyps (452 cases, 11.1%). This evidence concerns the gene IDH3A and digestive system disorder.